Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines

Hari Pujar

27 September 2024

Interview

Navigating the European landscape of advanced therapy funding and commercialization

Dmitry A Kuzmin

03 September 2024

Interview

Driving digital innovation for supply chain orchestration in cell and gene therapy

Christian Fuchs

28 August 2024

Interview

Insights into advanced therapies in the context of evolving funding and M&A environments

Lee Brown

26 March 2024

Interview

Wall Street analyst’s perspective: taking the pulse of the nucleic acid-based prophylactic & therapeutic vaccine sectors

Hartaj Singh

23 February 2024

Interview

Empowering the tissue engineered product field

Michael Lehmicke, Natalie Fekete

16 February 2024

Interview

A payment innovation framework to meet the urgent need in advanced therapies

Mark Trusheim

17 April 2023

Interview

Blazing a trail for commercial TCR T cell therapy

Helen Tayton-Martin

14 June 2022

Interview

Trends and considerations in cell and gene therapy M&A, partnering and IP

Ewan Townsend

11 May 2022

Interview

Building from the ground up: business culture learnings for cell and gene therapy biotechs

James Noble

01 February 2022

Interview

Critical success factors for tomorrow’s cellular immunotherapies

Peter Emtage

17 November 2021

Interview

Establishing gene therapies as a relevant, recognized and accessible therapeutic category

Tay Salimullah

10 November 2021

Interview

Analyzing trends and opportunities in the advanced therapy tool and service provider sectors

David Anderson

26 October 2021

Interview

Driving disruptive innovation in the ATMP field

Kerstin Papenfuss

06 October 2020

Interview

Analyzing current trends and future directions in I-O clinical development

Daina Graybosch

14 September 2020

Interview

From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

Parag Meswani

28 August 2020

Interview

Looking to the future of stem cell-derived immunotherapy

Peter Zandstra

17 June 2020

Interview

Understanding the drivers of success and failure in CAR T cell therapy

Jan Melenhorst

16 June 2020

Interview

Building for future success: the Syncona Partners model

Martin Murphy

31 January 2020

Interview

State of the Industry: The Financial, Clinical, and Scientific Landscape for Cell and Gene Therapies

Janet Lynch Lambert

31 January 2020

Interview

How commercial biopharma experience is shaping cell & gene therapy facility design

Niranjan Kulkarni, PhD, Allan Bream, Grace Linton, RA, AIA, LEED AP BD+C

07 October 2019

Interview